参考文献/References:
[1] Chaturvedi S,Bhattacharya P.Large artery atherosclerosis: carotid stenosis, vertebral artery disease, and intracranial atherosclerosis[J].Continuum(Minneap Minn),2014,20(2 Cerebrovascular Disease):323-334.
[2] Caplan LR,Wityk RJ,Glass TA,et al.New England medical center posterior circulation registry[J].Ann Neurol,2004,56(3):389-398.
[3] Jenkins JS,Patel SN,White CJ,et al.Endovascular stenting for vertebral artery stenosis[J].J Am Coll Cardiol,2010,55(6):538-542.
[4] Thompson MC,Issa MA,Lazzaro MA,et al.The natural history of vertebral artery origin stenosis[J].J Stroke Cerebrovasc Dis,2014,23(1):e1-e4.
[5] Shutze W,Gierman J,McQuade K,et al.Treatment of proximal vertebral artery disease[J].Vascular,2014,22(2):85-92.
[6] Markus HS,Larsson SC,Kuker W,et al.Stenting for symptomatic vertebral artery stenosis: the vertebral artery ischaemia stenting trial[J].Neurology,2017,89(12):1229-1236.
[7] Compter A,van der Worp HB,Schonewille WJ,et al.Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial[J].Lancet Neurol,2015,14(6):606-614.
[8] Coward LJ,McCabe DJH,Ederle J,et al.Long-term outcome after angioplasty and stenting for symptomatic vertebral artery stenosis compared with medical treatment in the carotid and vertebral artery transluminal angioplasty study(CAVATAS): a randomized trial[J].Stroke,2007,38(5):1526-1530.
[9] 蒋雄京,邹玉宝.锁骨下/颅外椎动脉狭窄的处理:中国专家共识[J].中国循环杂志,2019,34(6):523-532.
[10] Jenkins JS,Stewart M.Endovascular treatment of vertebral artery stenosis[J].Prog Cardiovasc Dis,2017,59(6):619-625.
[11] 闫宏伟,徐善才,张广,等.椎动脉起始部支架置入后再狭窄因素的研究进展[J].中国脑血管病杂志,2018,15(7):378-381.
[12] Gruber P,Braun C,Kahles T,et al.Percutaneous transluminal angioplasty using the novel drug-coated balloon catheter Sequent please NEO for the treatment of symptomatic intracranial severe stenosis: feasibility and safety study[J].J Neurointerv Surg,2019,11(7):719-722.
[13] Hayakawa N,Kodera S,Arakawa M,et al.Clinical outcome of drug-coated balloon versus scaffold device in patients with superficial femoral artery chronic total occlusion[J].Heart Vessels,2022,37(2):282-290.
[14] 张明超,鲁大胜.药物洗脱球囊在原位血管病变中的应用研究进展[J].中西医结合心脑血管病杂志,2020,18(19):3226-3229.
[15] 陈韵岱,王建安,刘斌,等.药物涂层球囊临床应用中国专家共识[J].中国介入心脏病学杂志,2016,24(2):61-67.
[16] 李宪东,霍龙文,宋康佳,等.药物洗脱球囊在脑动脉疾病治疗中的研究进展[J].中国脑血管病杂志,2020,17(12):766-771.
[17] Loh JP,Satler LF,Pendyala LK,et al.Use of emergency medical services expedites in-hospital care processes in patients presenting with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J].Cardiovascular Revascularization Medicine,2014,15(4):219-225.
[18] Stayman AN,Nogueira RG,Gupta R.A systematic review of stenting and angioplasty of symptomatic extracranial vertebral artery stenosis[J].Stroke,2011,42(8):2212-2216.
[19] Taylor RA,Siddiq F,Memon MZ,et al.Vertebral artery ostial stent placement for atherosclerotic stenosis in 72 consecutive patients: clinical outcomes and follow-up results[J].Neuroradiology,2009,51(8):531-539.
[20] Broussalis E,Kunz AB,Luthringshausen G,et al.Treatment of vertebral artery origin stenosis with a Pharos stent device: a single center experience[J].Interv Neuroradiol,2011,17(3):316-322.
[21] Chen WH,Huang F,Li M,et al.Incidence and predictors of the in-stent restenosis after vertebral artery ostium stenting[J].J Stroke Cerebrovasc Dis,2018,27(11):3030-3035.
[22] Che WQ,Jiang XJ,Dong H,et al.Effect of stenting for the proximal atherosclerotic extracranial vertebral artery stenosis[J].Zhonghua Xin Xue Guan Bing Za Zhi,2017,45(1):34-38.
[23] 刘佳明,潘鹏宇,陈立刚,等.紫杉醇药物涂层球囊成形术治疗症状性椎动脉开口处狭窄的疗效[J].中国临床神经外科杂志,2021,26(2):65-67.
[24] Wang MY,Wang F,Liu YS,et al.Comparison of Drug-coated balloons to bare metal stents in the treatment of symptomatic vertebral artery-origin stenosis: a prospective randomized trial[J].World Neurosurg,2021,154:e689-e697.
[25] Wang YB,Feng YD,Wang T,et al.Drug-coated balloon for vertebral artery origin stenosis: a pilot study[J].J Neurointerv Surg,2021,13(9):827-830.
[26] 朱碧峰,李芹,彭涛,等.椎动脉起始部支架置入术后再狭窄的危险因素分析[J].神经损伤与功能重建,2020,15(4):229-230, 244.
[27] Werner M,Bräunlich S,Ulrich M,et al.Drug-eluting stents for the treatment of vertebral artery origin stenosis[J].J Endovasc Ther,2010,17(2):232-240.
[28] Sun X,Ma N,Wang B,et al.The long term results of vertebral artery ostium stenting in a single center[J].J Neurointerv Surg,2015,7(12):888-891.
[29] 韩磊.椎动脉起始部狭窄支架置入治疗的长期随访研究[D].大连:大连医科大学,2018.
[30] Li MKA,Tsang ACO,Tsang FCP,et al.Long-term risk of in-stent restenosis and stent fracture for extracranial vertebral artery stenting[J].Clin Neuroradiol,2019,29(4):701-706.
[31] Loh JP,Barbash IM,Waksman R.The current status of drug-coated balloons in percutaneous coronary and peripheral interventions[J].EuroIntervention,2013,9(8):979-988.
[32] Gruber P,Berberat J,Kahles T,et al.Angioplasty using drug-coated balloons in ostial vertebral artery stenosis[J].Ann Vasc Surg,2020,64:157-162.
[33] Latib A,Colombo A,Castriota F,et al.A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO(balloon elution and late loss optimization)study[J].J Am Coll Cardiol,2012,60(24):2473-2480.
[34] Mieres J,Fernandez-Pereira C,Risau G,et al.One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the diabetic argentina registry(DEAR)[J].Cardiovasc Revasc Med,2012,13(5):265-271.
[35] Fanelli F,Cannavale A,Boatta E,et al.Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the debellum randomized trial[J].J Endovasc Ther,2012,19(5):571-580.
[36] Ben Kridis W,Toumi N,Khanfir A.Chemotherapy-induced peripheral neurotoxicity: single-centre prospective study[J].BMJ Support Palliat Care,2023:spcare-sp2023.
[37] Hershman DL,Weimer LH,Wang AT,et al.Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy[J].Breast Cancer Res Treat,2011,125(3):767-774.
[38] 孙钰朋,杜福映,郭利娟,等.高效液相色谱法测定药物涂层球囊中紫杉醇含量的不确定度评定[J].化学分析计量,2022,31(8):72-76.
[39] 中国抗癌协会多原发和不明原发肿瘤专业委员会,胡夕春,罗志国,等.中国紫杉类药物剂量密集化疗方案临床应用专家共识[J].中国癌症杂志,2019,29(11):910-920.
[40] Clever YP,Rosenkranz S,Böhm M,et al.Hotline update of clinical trials and registries presented at the ACC and SCAI-ACCi2 meeting 2008 in Chicago[J].Clin Res Cardiol,2008,97(7):409-417.